Close
UCL presentations at The Union annual conference, 15-18 Nov 2023
The Union conference is a major TB research and policy event.
Below are presentations by UCL-TB affiliated people. All timings are CET.
| Wednesday 15th November | |||
Ibrahim Abubakar
| Panel discussion | WHO Global #EndTB Symposium 2023 Panel discussion: Breakthroughs and opportunities to accelerate the TB response | Wednesday, 15 Nov 2023, 10:30 - 11:20 |
Helgard Claassen/ Al Leslie | Oral presentation | OA02 Subclinical TB: How to recognize it when you see it? D1: TB epidemiology across the life course
OA02-213-15 3-year outcomes in individuals with microbiologically proven sub-clinical TB detected in a population-based survey in rural KwaZulu-Natal, South Africa | Wednesday, 15 Nov 2023 11:14 - 11:23
|
Ibrahim Abubakar | Plenary | PL-01 Closing the gap between evidence and implementation | Wednesday, 15 Nov 2023, 12:00 - 13:00
|
Gareth Hughes | Oral presentation
| OA06 Safety of regimens for R-R B3: Clinical trials and operational research for new treatments for TB (for adults and children)
OA06-243-15 Predictive analyses of QT prolongation from ECG monitoring in the STREAM Stage 2 trial | Wednesday, 15 Nov 2023 15:37 - 15:45 |
Angela Crook | Symposia | SP06 Progress and innovation in developing shorter treatment regimens for people with TB B3: Clinical trials and operational research for new treatments for TB (for adults and children)
Duration-ranging in Phase 2 trials: UNITE4TB and the MAMS-ROCI Design | Wednesday, 15 Nov 2023 15:47 - 16:01 |
Andrew Nunn | Chair | OA07 Treatment outcome of all oral-short course regimens for RR.TB B3: Clinical trials and operational research for new treatments for TB (for adults and children) | Wednesday, 15 Nov 2023 16:45 - 18:15 |
Al Story | Symposia | SP10 Providing people-centred TB care for vulnerable populations E2: Key affected populations: behavioural, social, and cultural issues and contexts
Active case-finding and differentiated care models to accelerate TB elimination among key affected populations in Delhi, India | Wednesday, 15 Nov 2023 17:04 - 17:18 |
Ruth Goodall | Oral presentation
| OA07 Treatment outcome of all oral-short course regimens for RR.TB B3: Clinical trials and operational research for new treatments for TB (for adults and children)
OA07-252-15 Long-term outcomes in STREAM Stage 2: A phase 3 trial in rifampicin-resistant TB
| Wednesday, 15 Nov 2023 17:26 - 17:35 |
| Thursday 16th November | |||
Jess Potter | Union Side Session | Union Side Session: Partnering with Policymakers to Implement UNHLM 2023 08:20 - 08:40 Panel 1: Building a diverse community of advocates | Thursday, 16 Nov 2023 08:00 - 10:00 CET |
Jess Potter | Community Connect | CC-09 Reflecting and learning from community, academic and health professional engagement with the UN High-Level Meeting on TB for actionable next steps Track 3: Political contexts for community led advocacy and accountability
Using our voice to call for change – an academic and health professional's perspective | Thursday, 16 Nov 2023 10:45 - 10:55 |
| Gabriele Pollara | TB Science | Altered interleukin-6 signalling and risk of TB disease: a meta-analysis and trans-ancestry Mendelian randomisation study | Thursday, 16 Nov 2023 11:05 - 11:10, Salle Maillot 5 |
| Sanjib Bhakta | TB Science | TBS2C: Host-directed therapy Anti-inflammatory drugs for TB | Thursday, 16 Nov 2023 17.13 - 17.23 |
| Friday 17th November | |||
Asad Zaidi | Symposia
| SP28 An International Consensus on Early TB (ICE-TB) - the path to programmatic impact C2: Care and treatment of TB (drug-sensitive and drug-resistant TB)
An International Consensus for Early TB (ICE-TB): Results from the 1st Early TB Symposium | Friday, 17 Nov 2023 10:20 - 10:32 |
Hanif Esmail | Symposia | SP28 An International Consensus on Early TB (ICE-TB) - the path to programmatic impact C2: Care and treatment of TB (drug-sensitive and drug-resistant TB)
Interventions for early TB: Developing interventions for a new framework | Friday, 17 Nov 2023 10:57 - 11:10 |
Gabriele Pollara | E-poster | EP17 Immunology for early TB diagnosis A1: Immunology - research into diagnostics and immunity
EP17-1153-17 Altered interleukin-6 signalling and risk of TB disease: A meta-analysis and Mendelian randomisation study | Friday, 17 Nov 2023 12:55 - 13:00 Salle Maillot 1 |
Ankur Gupta-Wright | Symposia | SP36 New tests for TB screening, diagnosis and treatment monitoring: what do we need? A3: TB diagnostics, including drug-resistance determination – Technical aspects and new developments
Patient-pathway analysis of TB treatment monitoring | Friday, 17 Nov 2023 16:01 - 16:15 |
Hanif Esmail | Satellite session | SS17 Rethinking clinical trial design to accelerate improved treatment options for TB-affected communities: Innovative collaborations redefining TB drug and regimen development B3: Clinical trials and operational research for new treatments for TB (for adults and children) UNITE4TB-01: A new PARADIGM of evaluating novel drugs | Friday, 17 Nov 2023 Session: 18:30 – 20:00 18:49 - 18:56 |
| Saturday 18th November | |||
| Stella Fabiane | Oral presentation | OA59 TB control: from diagnosis to treatment outcome OA59-667-18 Does the choice of fluoroquinolone affect treatment outcomes in rifampicin-resistant TB? | Saturday, 18 Nov 2023 08:11 - 08:20 |
Ruth Goodall
| Oral presentation
| OA59 TB control: from diagnosis to treatment outcome C2: Care and treatment of TB (drug-sensitive and drug-resistant TB)
OA59-663-18 Creating a global individual patient data platform for TB treatment, TB-IPD | Saturday, 18 Nov 2023 08:35 - 08:44 |